Summary: A multicentre trial from five medical departments in Oslo has been carried out to determine the value in women patients of one year's long-term anticoagulant therapy. Follow-up long-term laboratory control and anticoagulant dosage were performed at one centre (the Rikshospitalet). One hundred and fifty-nine patients were assigned randomly into two similar well-matched groups (control and treatment). Dosage was controlled by Thrombotest, aiming at 10-20% levels, and 50% of the tests were less than 14%. Compared with the control group, the treatment group showed a significant reduction in mortality and in reinfarction rate. No serious bleeding complications occurred. It is concluded that women benefit as much as men from long-term anticoagulant therapy.
Introduction
In 1960 the situation regarding long-term anticoagulant therapy in coronary heart disease seemed to be that some effect on both mortality and morbidity had been demonstrated in male patients, though there was apparently little effect, if any, in females (Bjerkelund, 1957; M.R.C., 1959) . Nevertheless, most published studies included relatively few women, and the authors had been reluctant to draw conclusions about any sex difference. Thus the value of long-term anticoagulant therapy in women was far from settled.
With this background a co-operative study involving five medical departments in Oslo was launched in 1960. By giving anticoagulant therapy for one year after the first myocardial infarction to a fairly large number of female patients, and by comparing their mortality and reinfarction rate with that of an adequate control group, we hoped to answer the question whether long-term anticoagulant therapy after myocardial infarction in females was in fact beneficial or not. The following reasons for exclusion of a patient were adopted: (1) hospital stay for more than eight weeks during the acute infarction; (2) infarction more than one month old on admission; (3) anticoagulant therapy already started before the attack; (4) general bleeding tendency; (5) a history of recurrent gastrointestinal bleeding or of a bleeding ulcer within the last six months; (6) hypertensive fundal changes of grade III or IV; (7) relative heart volume 550 or more millilitres per square metre of body surface, or aortic valvular disease; (8) obvious congestive heart failure on discharge from hospital; (9) cirrhosis of the liver, chronic renal insufficiency (serum creatinine more than 1.5 mg./100 ml.), pregnancy; (10) any serious disease likely to lead to death within one year, or any reason which would make it unlikely that the patient would be able to carry out the treatment.
Material and Methods
During the stay in hospital for the acute infarction all patients received routine treatment, including anticoagulant. Allocation of the patients to the treatment or the control group was done by means of a table of random numbers, with the restriction (unknown to the participating doctors) that the number in the two groups should be equal after every second allocation. Separate lists were used for patients under 60 years and for those aged 60 and over. One group received oral anticoagulant therapy (dicoumarol, warfarin, or phenindione) with the aim of reducing clotting activity to between 10 and 20%, measured with the Thrombotest method. The other group received the same oral anticoagulant but in token doses only, resulting in insignificant reduction of the clotting activity. Both groups had regular control tests on clotting activity, at least every four weeks, at the Institute for Thrombosis Research at the Rikshospitalet. All patients had a clinical examination and E.C.G. investigation, 1, 4, 8, and 12 months after the start of the observation period, in the same medical department to which they had been admitted for their myocardial infarction.
The patients were asked to appear at the Institute for Thrombosis Research one week after discharge from hospital. The observation period began one week later in order to obtain the planned anticoagulant level in both groups at the start of the observation period, which lasted exactly one year for each patient.
If a patient in the control group sustained a reinfarction she was readmitted to hospital and was given intensive anticoagulant therapy, but she returned to her previous treatment when discharged from start of the observation period-that is, during the 14 days after discharge from hospital while the anticoagulant therapy they had had during the acute infarction was being tapered off. The difference in mortality in patients between 60 and 70 years, eight against one, is statistically significant (P<0.05).
One of the two deaths in the treated group occurred in the first month and the other in the fifth month. In the control group three patients died in the first month, three later in the first quarter, two in the second quarter, and one in the fourth quarter.
Necropsy in three patients (all in the control group), two of whom had died suddenly, showed widespread coronary atherosclerosis. In two patients an old infarction was found, but no fresh infarction or fresh coronary thrombus. In the third patient a fresh thrombus and infarction were found, as well as the old infarction.
Two patients in the treated group died at home after an acute attack of retrosternal pain, death being presumably due to recurrent infarction. Of the control patients in whom postmortem examination was not carried out, one died suddenly, four had recurrent infarction clinically,, and one died in an attack of acute pulmonary oedema without retrosternal pain. Thus all deaths were presumably cardiac. The mean Thrombotest value achieved was 15.9%, which compares favourably with previous studies from Scandinavia (Bjerkelund, 1957; Borchgrevink, 1960 Borchgrevink, , 1962 Harvald et al., 1962; Aspenstrom and Bengtsen, 1964; Sorensen et al., 1968 ), but which is higher than that recently reported from Holland (Loeliger et al., 1967) . Half the tests were between 5 and 14% Thrombotest, which is satisfactory. The bleeding complications were all trivial, and no patient had to be admitted to hospital or to stop treatment because of them.
Reinfarction
Our (Harvald et al., 1962; Seaman et al., 1964) , and hence cannot be compared with the present study.
An editorial in the British Medical 7ournal (1964) , while advocating long-term anticoagulant therapy in younger men, concluded: ". . . there seems to be little justification for giving women long-term anticoagulant therapy." Nevertheless, there is no valid theoretical or practical reason for believing that the effect of long-term anticoagulant therapy is materially different in the two sexes. However, while in men the effect seems to be more pronounced below the ages of 55 to 60 years, in women our study shows that there is an effect on both the mortality and the reinfarction rate between the ages of 60 and 70. Our study does not answer the question whether younger women would also benefit from long-term anticoagulant therapy, though there is a suggestion of an effect on the reinfarction rate.
The present study cannot answer how long the therapy should last. The effect seems to be maximal during the first three months after discharge from hospital, but our results do not rule out that the effect lasts longer. From our study and from recently published accounts we think it is logical to adopt the same policy on instituting and maintaining long-term anticoagulant therapy in women as in men. By carefully crossanalysing all the data we had hoped to be able to correlate the positive effect of the treatment with certain features in the patient's history. We were, however, unable to find any subgroup of patients in whom the therapy was effective and other subgroups in whom it was ineffective. It may be argued, however, that with our method of selection we were already dealing with a subgroup of female patients with myocardial infarction.
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Introduction
From 1958 onwards cases of pleural and pulmonary fibrosis, have been discovered in men working at the Royal Dockyard. at Devonport, partly in the course of routine examinations. in the dockyard and partly among patients with symptoms. referred to the local chest clinic. Further investigation has. confirmed an association between these conditions and exposure to asbestos, and by 1964, when the first case of pleural mesothelioma was identified, it was evident that a serious increase in the hazards arising from the use of this material had.
developed.
In 1966 it became practicable to carry out a large-scale survey with a radiographic technique of adequate quality, and the opportunity was taken to incorporate a one-in-ten sample of workers. This paper is concerned mainly with the results of the survey, and in particular with the prevalence of abnormalities attributed to asbestos and their relation to.
exposure. t Medical Director, Mass Radiography Centre, Plymouth.
